Analyst Price Target is $35.00
▲ +68.03% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Personalis in the last 3 months. The average price target is $35.00, with a high forecast of $50.00 and a low forecast of $28.00. The average price target represents a 68.03% upside from the last price of $20.83.
Current Consensus is
The current consensus among 9 polled investment analysts is to buy stock in Personalis. This Buy consensus rating has held steady for over two years.
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.